Her name was Henrietta Lacks, but scientists know her as HeLa. Born a poor black tobacco farmer, her cancer cells -- taken without her knowledge -- became a multimillion-dollar industry and one of the most important tools in medicine. Yet Henrietta's family did not learn of her 'immortality' until more than twenty years after her death, with devastating consequences . . . Rebecca Skloot's fascinating account is the story of the life, and afterlife, of one woman who changed the medical world forever. Balancing the beauty and drama of scientific discovery with dark questions about who owns the stuff our bodies are made of, The Immortal Life of Henrietta Lacks is an extraordinary journey in search of the soul and story of a real woman, whose cells live on today in all four corners of the world. 'A fascinating, harrowing, necessary book' Hilary Mantel, Guardian 'A heartbreaking account of racism and injustice' Metro 'A fine book... a gripping read...The book has deservedly been a huge bestseller in the US. It should be here, too' Sunday Times Rebecca Skloot is an award-winning science writer whose articles have appeared in The New York Times Magazine; O, The Oprah Magazine; Discover; Prevention; Glamour; and others. She has worked as a correspondent for NPR’s Radiolab and PBS’s NOVAscienceNOW, and is a contributing editor at Popular Science magazine and guest editor of The Best AmericanScience Writing 2011. Her work has been anthologized in several collections, including The Best Creative Nonfiction. She is a former vice president of the National Book Critics Circle, and has taught creative non-fiction and science journalism at the University of Memphis, the University of Pittsburgh, and New York University. She lives in Chicago. The Immortal Life of Henrietta Lacks is her first book. It is being translated into more than twenty languages and adapted into an HBO film produced by Oprah Winfrey and Alan Ball. For more information, visit her website at RebeccaSkloot.com, where you’ll find links to follow her on Twitter and Facebook.